CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells Du, Juan , Lopez-Verges, Sandra , Pitcher, Brandelyn N. ... - - Cancer Immunol Res - 2014 Manuscript - Primary - Primary - Lymphoma - CALGB-150905 , CALGB-50402 , CALGB-50701
Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20) Grant, B. , Leonard, J. P. , Johnson, J. L. , Kostakoglu, L. , Hsi, E. ... - - Blood - 2010 Abstract - Primary - Primary - Lymphoma - CALGB-50701
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Grant, Barbara W , Jung, Sin-Ho , Johnson, Jeffrey L ... - - Cancer - 2013 Manuscript - Primary - Primary - Lymphoma - CALGB-50701
Early relapse of follicular lymphoma after rituximab-based biologic doublet upfront therapy is associated with increased risk of death: a combined analysis from CALGB/Alliance Studies 50402, 50701 and 50803 Lansigan, Frederick , Barak, Ian , Pitcher, Brandelyn , Jung, Sin-Ho ... - ASH - Blood - 2016 Abstract - Secondary-not-in-original - Meta-Analysis - Lymphoma - CALGB-50402 , CALGB-50701 , CALGB-50803
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials Lansigan, Frederick , Barak, Ian , Pitcher, Brandelyn , Jung, Sin‐Ho ... - - Cancer Med - 2018 Manuscript - Secondary-not-in-original - Meta-Analysis - Lymphoma - CALGB-50402 , CALGB-50701 , CALGB-50803
Biomarkers for Risk Stratification in Patients with Previously Untreated Follicular Lymphoma Receiving Anti-CD20-Based Biologic Therapy Sohani, Aliyah R. , Maurer, Matthew J. , Giri, Sharmila ... - - Am J Surg Pathol - 2021 Manuscript - Secondary-not-in-original - Meta-Analysis - Correl Sci NOS - CALGB-50402 , CALGB-50701 , CALGB-50803 , CALGB-50901
Interfollicular CD10 Expression and Follicular PD1 Tumor-infiltrating lymphocytes as biologic risk factors in patients with previously untreated follicular lymphoma receiving rituximab-based biologic therapy: An Alliance correlative science study (CALGB 50901, 50402, 50701, 50803, 50401) Sohani, Aliyah R. , Pitcher, Brandy , Chadburn, Amy , Said, Jonathan ... - ASH - Blood - 2015 Abstract - Secondary-not-in-original - Meta-Analysis - Correl Sci NOS - CALGB-50401 , CALGB-50402 , CALGB-50701 , CALGB-50803 , CALGB-50901
Toxicities and related outcomes of elderly patients (≥65 years) with hematologic malignancies in the contemporary era (Alliance A151611) Tallarico, Michael , Foster, Jared , Seisler, Drew ... - ASH - Blood - 2016 Abstract - Primary - Primary - Older Adult - A151611 , CALGB-10101 , CALGB-10404 , CALGB-10501 , CALGB-19805 , CALGB-19901 , CALGB-50002 , CALGB-50103 , CALGB-50201 , CALGB-50401 , CALGB-50402 , CALGB-50501 , CALGB-50602 , CALGB-50701 , CALGB-50803
